Tunicamycin from Streptomyces sp.
SIGMA/T7765
CAS Number: 11089-65-9
MDL Number: MFCD00065709
Product Type: Chemical
| antibiotic activity spectrum | fungi |
| viruses | |
| InChI | 1S/C37H60N4O16/c1-18(2)12 |
| InChI key | YJQCOFNZVFGCAF-WPTOCQRYSA |
| mode of action | protein synthesis | interferes |
| Quality Level | 300 ![]() |
| SMILES string | CC(C)CCCCCCCCC=CC(=O)N[ |
| solubility | 95% ethanol: soluble 1 mg/mL, clear to faintly hazy |
| acetone: insoluble | |
| aqueous base: insoluble | |
| chloroform: insoluble | |
| dioxane: soluble <1 mg/mL | |
| DMF: soluble >10 mg/mL | |
| DMSO: soluble 4.9-5.1 mg/mL, clear to slightly hazy, colorless to yellow | |
| ethyl acetate: insoluble | |
| methanol: slightly soluble 4.9-5.1 mg/mL | |
| methanol: soluble 4.9-5.1 mg/mL, clear to slightly hazy, colorless to yellow | |
| pyridine: >10 mg/mL | |
| THF: soluble <1 mg/mL | |
| storage temp. | 2-8°C |
| Application: | Tunicamycin has been used to study the effect of N-linked glycosylation of human proton-coupled folate transporter (HsPCFT) in HeLa cells. Tunicamycin has also been used to study the functional effects of coxsackievirus and adenovirus receptor (CAR) glycosylation in COS-7 cells. Tunicamycin from Streptomyces sp. has been used to inhibit N-glycosylation in cell culture experiments. |
| Biochem/physiol Actions: | Blocks the formation of protein N-glycosidic linkages. |
| General description: | Chemical structure: nucleoside |
| General description: | Contains homologues A,B,C, and D. Composition may vary from lot to lot. Actual content given on label. |
| General description: | Tunicamycin is an antibiotic and a glycosylation inhibitor. Its mode of action includes blocking human UDP-HexNAc:polyprenol-P HexNAc-1-P enzymes in the enzyme GlcNAc phosphotransferase (GPT). Glycosylation is a major post-translational modification that plays a critical role in glycoprotein folding, stability, and subcellular localization, as well as in the biological functions of the glycoprotein. Abnormal glycosylation has been identified as a signature of cancer and has been shown to play a significant role in tumor progression, metastasis, and chemoresistance. Research shows tunicamycin exhibits antitumor action. Furthermore, tunicamycin inhibition of N-glycosylation ultimately results in the build-up of unstructured proteins in the endoplasmic reticulum (ER) lumen, potentially leading to ER stress. Tunicamycin also exhibits antibacterial and antifungal actions. It blocks the formation of protein N-glycosidic linkages by inhibiting the transfer of N-acetylglucosamine 1-phosphate to dolichol monophosphate. Tunicamycin also Inhibits bacterial and eukaryote N-acetylglucosamine transferases and prevents the formation of N-acetylglucosamine lipid intermediates. |
| Packaging: | 1, 5, 10, 50 mg in glass bottle |
| Preparation Note: | Tunicamycin dissolves in DMSO at 4.9-5.1 mg/ml and yields a clear to very slightly hazy, colorless to yellow solution. Furthermore, tunicamycin is soluble in DMF (>10 mg/ml), pyridine (>10 mg/ml), water (<5 mg/ml, pH 9.0), dioxane (<1 mg/ml) and THF. However, it is insoluble in other organic solvents such as acetone, chloroform, and ethyl acetate, and in aqueous solutions with pH <6. Aqueous solutions can be prepared from stock solutions by diluting with water at pH 8-10 or with buffers with pH >7, preferably >8. Tunicamycin will not dissolve in phosphate buffer, pH 8, at 1 mg/ml, even with heating, but solubility can be achieved by raising the pH to 9 and back titrating to pH 7-8. |
| Symbol | GHS06 |
| Signal word | Danger |
| Hazard statements | H300 |
| Precautionary statements | P264 - P270 - P301 + P310 - P405 - P501 |
| Hazard Codes | T+ |
| Risk Statements | 28 |
| Safety Statements | 28-37/39-45 |
| RIDADR | UN 3462 6.1 / PGII |
| WGK Germany | WGK 3 |
| Flash Point(F) | Not applicable |
| Flash Point(C) | Not applicable |
| Storage Temp. | 2-8°C |
| UNSPSC | 51111800 |


